Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 244

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 244
---
 date immediately before the date of the next annual stockholder meeting, subject to continued service through such vesting date. In the event of a change in control, as defined in our 2021 Plan (or its successor plan, as applicable), each non-employeedirector’s then outstanding equity awards covering shares of our common stock will accelerate vesting in full, provided that he or she remains a non-employeedirector through the date of the closing of the change in control. Each Initial Grant and Annual Grant will be granted under our 2021 Plan (or its successor plan, as applicable) and form of award agreement under such plan. These awards will have a maximum term to expiration of 10 years from their grant and a per share exercise price equal to 100% of the fair market value of a share of our common stock on the award’s grant date. - 172 -

The 2021 Plan includes a maximum annual limit of $750,000 of cash compensation and equity awards that may be paid, issued or granted to a non-employeedirector in any fiscal year (increased to $1,000,000 in the fiscal year in which the non-employeedirector joins the board of directors). For purposes of these limitations, the value of an equity award is based on its grant date fair value. Any cash compensation paid or equity awards granted to a person for his or her services as an employee, or for his or her services as a consultant (other than as a non-employeedirector), will not count for purposes of the limitation. The maximum limit does not reflect the intended size of any potential compensation or equity awards to our non-employeedirectors. 2024 Director Compensation Table The following table sets forth information for the year ended December 31, 2024, regarding the compensation awarded to, earned by or paid to our non-employeedirectors. Directors who are also our employees receive no additional compensation for their service as a director. The compensation received by Drs. Lennon and Desai as employees of the Company, and Dr. Desai’s compensation received as a non-employee director since October 1, 2024, is presented in “ Executive Compensation-Summary Compensation Table”.

| Name                               |     | Fees Earned 
 or          
 Paid in     
 Cash($)     |        |     | Option        
 Awards ($)(1) |         |     | Total($) |         |
| Caley Castelein, M.D. (2)          |     |